New investigational drugs for the treatment of neuropathic pain

Expert Opinion on Investigational Drugs

Volumn 23, Issue 8, 2014, Pages 1093-1104

  Sałat, Kinga ^a   Kowalczyk, Paula ^a   Gryzło, Beata ^a   Jakubowska, Anna ^a   Kulig, Katarzyna ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Angiotensin II AT2 receptor antagonists; Inhibitors of Nav1.7 channels; N type calcium channel antagonists; Neuropathic pain; Phase II clinical studies; Tanezumab

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL T TYPE; EMA 401; NERVE GROWTH FACTOR; SODIUM CHANNEL NAV1.6; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT; NEW DRUG;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; CENTRAL SENSITIZATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GENOMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE FIBER; NERVE SPROUTING; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL SENSITIZATION; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIZATION; SENSORY NERVE; ANIMAL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; NEURALGIA; PATHOPHYSIOLOGY; PROCEDURES;

ANALGESICS; ANIMALS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NEURALGIA;

EID: 84904286689     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.916688     Document Type: Review

References (74)

1. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain 2011;152: 2204-5
2. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152: 14-27
3. Haanpää M. The assessment of neuropathic pain patients. Pain Manag 2013;3: 59-65
4. Backonja MM. Defining neuropathic pain. Anesth Analg 2003;97: 785-90
5. Babos MB, Grady B, Wisnoff W, et al. Pathophysiology of pain. Dis Mon 2013;59: 330-58
6. Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111: 105-11
7. Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: Current evidence and future directions. Expert Rev Neurother 2005;5: 823-30
8. Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther 2004;26: 951-79
9. Backonja M, Woolf CJ. Future directions in neuropathic pain therapy: Closing the translational loop. Oncologist 2010;15(Suppl 2): 24-9
10. Mick G, Baron R, Finnerup NB. What is localized neuropathic paiñ A first proposal to characterize and define a widely used term. Pain Manag 2012;2: 71-7
11. Hartrick CT. Noradrenergic reuptake inhibition in the treatment of pain. Expert Opin Investig Drugs 2012;21: 1827-34
12. Richards N, McMahon SB. Targeting novel peripheral mediators for the treatment of chronic pain. Br J Anaesth 2013;111: 46-51
13. Lotsch J, Doehring A, Mogil JS, et al. Functional genomics of pain in analgesic drug development and therapy. Pharmacol Ther 2013;139: 60-70
14. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118: 289-305
15. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8: 149-54
16. Burgess G, Williams D. The discovery and development of analgesics: New mechanisms, new modalities. J Clin Invest 2010;120: 3753-9
17. Salat K, Moniczewski A, Librowski T. Transient receptor potential channels-emerging novel drug targets for the treatment of pain. Curr Med Chem 2013;20(11): 1409-36
18. Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics 2009;6: 663-78
19. Colombo E, Francisconi S, Faravelli L, et al. Ion channel blockers for the treatment of neuropathic pain. Future Med Chem 2010;2: 803-42
20. Clark AK, Old EA, Malcangio M. Neuropathic pain and cytokines: Current perspectives. J Pain Res 2013;21: 803-14
21. Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a 'hot' medicine is reignited. Expert Opin Pharmacother 2010;11: 1359-71
22. Choi KH. The design and discovery of T-Type calcium channel inhibitors for the treatment of central nervous system disorders. Expert Opin Drug Discov 2013;8: 919-31
23. Szallasi A, Sheta M. Targeting TRPV1 for pain relief: Limits, losers and laurels. Expert Opin Investig Drugs 2012;21: 1351-69
24. Pexton T, Moeller-Bertram T, Schilling JM, et al. Targeting voltagegated calcium channels for the treatment of neuropathic pain: A review of drug development. Expert Opin Investig Drugs 2011;20: 1277-84
25. Todorovic SM, Jevtovic-Todorovic V. T-Type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol 2011;163: 484-95
26. Yang P, Wang L, Xie XQ. Latest advances in novel cannabinoid CB2 ligands for drug abuse and their therapeutic potential. Future Med Chem 2012;4: 187-204
27. Gether U, Andersen PH, Larsson OM, et al. Neurotransmitter transporters: Molecular function of important drug targets. Trends Pharmacol Sci 2006;27: 375-83
28. Dib-Hajj SD, Binshtok AM, Cummins TR, et al. Voltage-gated sodium channels in pain states: Role pathophysiology and target for treatment. Brain Res Rev 2009;60: 65-83
29. Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol 2011;2: 1-54
30. Zhang XF, Shieh CC, Chapman ML, et al. A-887826 is a structurally novel, potent and voltage-dependent Nav1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats. Neuropharmacology 2010;59: 201-7
31. Nanayakkara B, Phillips D, Russell M. The molecular pathogenesis of primary erythromelalgia, a painful inherited syndrome-An update. MSJA 2012;4: 33-8
32. Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9: 413-24
33. Rahman W, Dickenson AH. Voltage gated sodium and calcium channel blockers for the treatment of chronic inflammatory pain. Neurosci Lett 2013;557: 19-26
34. Eijkelkamp N, Linley JE, Baker MD, et al. Neurological perspectives on voltage-gated sodium channels. Brain 2012;35: 2585-612
35. Wickenden A. Ion channel drug discovery: Challenges and future directions. Future Med Chem 2012;4: 661-79
36. Ali Z, Palmer JE, Goli V. Anticonvulsant clinical. In: McMahon S, Koltzenburg M, Tracey I, Turk D, editors. Wall and Melzack's texbook of pain. Elsevier; Barcelona: 2006
37. Chapman ML, Printzenhoff D, Lin Z, et al. Characterization of a novel subtype-selective inhibitor of human Nav1.7 voltage-dependent sodium channels, 140.06/C25, 2012 Neuroscience Meeting Planner. Society for Neuroscience; New Orleans, LA: 2012. Online
38. Evaluation of the efficacy and safety of single doses of PF-05089771 in patients with primary (inherited) erythromelalgia (IEM). Available from: Http: // clinicaltrials.gov/ct2/show/ NCT01769274?term=PF-05089771&rank=7
39. Lotsch J, Geisslinger G. Pharmacogenetics of new analgesics. Br J Pharmacol 2011;163: 447-60
40. Zakrzewska JM, Palmer J, Ettlin DA, et al. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials 2013;14: 402
41. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006;52(1): 77-92
42. Goldberg YP, Price N, Namdari R, et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain 2012;153: 80-5
43. Goldberg YP, Pimstone SN, Namdari R, et al. Human Mendelian pain disorders: A key to discovery and validation of novel analgesics. Clin Genet 2012;82: 367-73
44. Crow M, Denk F, McMahon SB. Genes and epigenetic processes as prospective pain targets. Genome Med 2013;5: 12
45. Perret D, Luo ZD. Targeting voltagegated calcium channels for neuropathic pain management. Neurotherapeutics 2009;6: 679-92
46. Vink S, Alewood PF. Targeting voltagegated calcium channels: Developments in peptide and small-molecule inhibitors for trearment of neuropathic pain. Br J Pharmacol 2012;167: 970-89
47. Corrigan MHN. Calcium channel treats chronic pain. Drug Discovery and Development. 2012. Available from: Www.dddmag.com/articles/2012/05/ calcium-channel-Treats-chronic-pain
48. Lee M, Snutch T. Z160: A potent and state-dependent, small molecule blocker of N-Type calcium channels effective in nonclinical models of neuropathic pain. J Pain 2013;14: S71
49. Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy. Available from: Http: //clinicaltrials.gov/ct2/show/ NCT01655849?term=Z160&rank=1
50. Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia (PHN). Available from: Http: // clinicaltrials.gov/ct2/show/ NCT01757873?term=Z160&rank=2
51. Jacus MO, Uebele VN, Renger JJ, Todorovic SM. Presynaptic CaV channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci 2012;32: 9374-81
52. Tringham E, Powell KL, Cain SM, et al. T-Type calcium channel blockers that attenuate thalamic buers firing and suppress absence seizures. Sci Transl Med 2012;4: 1-13
53. Short G, Lee M, Snutch T. Z944: A first in-class T-Type calcium channel blocker effective in nonclinical models of acute and inflammatory pain J Pain. 2013;14: S71
54. Hassan P, Ramesh K, Yanbing D, et al. N-piperidinyl acetamide derivatives as calcium channel blockers. US patent US8569344; 2013
55. Nemoto W, Nakagawasai O, Yaoita F, et al. Angiotensin II produces nociceptive behavior through spinal AT1 receptormediated p38 mitogen-Activated protein kinase activation in mice. Mol Pain 2013;9: 38
56. Pavel J, Tang H, Brimijoin S, et al. Expression and transport of Angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain Res 2008;1246: 111-22
57. Pavel J, Oroszova Z, Hricova L, et al. Effect of subpressor dose of angiotensin II on pain-related behavior in relation with neuronal injury and activation of satellite glial cells in the rat dorsal root ganglia. Cell Mol Neurobiol 2013;33: 681-8
58. Saavedra JM, Ando H, Armando I, et al. Anti-stress and anti-Anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 2005;128: 227-38
59. Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2013;17: 1012-26
60. Gallinat S, Yu M, Dorst A, et al. Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res 1998;57: 111-22
61. Tan YH, Li K, Chen XY, et al. Activation of Src family kinases in spinal microglia contributes to formalin-induced persistent pain state through p38 pathway. J Pain 2012;13: 1008-15
62. Smith MT, Woodruff TM, Wyse BD, et al. A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-Activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med 2013;14: 1557-68
63. Smith MT, Wyse BD, Edwards SR, et al. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: Comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med 2013;14: 692-705
64. Smith MT, Wyse BD. Method of treatment or prophylaxis. US patent US7795275; 2010
65. Smith MT. Method of treatment or prophylaxis inflammatory pain. Patent EP1996183; 2008
66. Takai S, Song K, Tanaka T, et al. Antinociceptive effects of angiotensinconverting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 1996;59: PL331-6
67. Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administrated highly selective angiotensin II type 2 receptor antagonist, as novel treatment for postherpetic neuralgia: A randomized, double-blind, placebocontrolled phase 2 clinical trial. Lancet 2014; Epub ahead of print
68. Available from: Www.anzctr.org
69. Kumar V, Mahal BA. NGF-The TrkA to successful pain treatment. J Pain Res 2012;5: 279-87
70. Seidel MF, Wise BL, Lane NE. Nerve growth factor: An update on the science and therapy. Osteoarthritis Cartilage 2013;21: 1223-8
71. McKelvey L, Shorten GD, O'Keeffe GW. Nerve growth factormediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem 2013;124: 276-89
72. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: What is the therapeutic potential? BioDrugs 2008;22: 349-59
73. Sanga P, Katz N, Polverejan E, et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain 2013;154: 1910-19
74. Bannwarth B, Kostine M. Targeting Nerve Growth Factor (NGF) for pain management: What does the future hold for NGF antagonistš Drugs 2014; Epub ahead of print.